Brii Biosciences Limited - Asset Resilience Ratio
Brii Biosciences Limited (7SS) has an Asset Resilience Ratio of 22.82% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Brii Biosciences Limited total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Brii Biosciences Limited's Asset Resilience Ratio has changed over time. See what is Brii Biosciences Limited's book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Brii Biosciences Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Brii Biosciences Limited market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €567.24 Million | 22.82% |
| Total Liquid Assets | €567.24 Million | 22.82% |
Asset Resilience Insights
- Good Liquidity Position: Brii Biosciences Limited maintains a healthy 22.82% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Brii Biosciences Limited Industry Peers by Asset Resilience Ratio
Compare Brii Biosciences Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.10% |
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 4.52% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 35.56% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Brii Biosciences Limited (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Brii Biosciences Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 48.66% | €1.32 Billion ≈ $1.54 Billion |
€2.71 Billion ≈ $3.16 Billion |
-19.22pp |
| 2023-12-31 | 67.88% | €2.17 Billion ≈ $2.54 Billion |
€3.20 Billion ≈ $3.74 Billion |
+14.61pp |
| 2022-12-31 | 53.27% | €1.81 Billion ≈ $2.11 Billion |
€3.39 Billion ≈ $3.97 Billion |
+39.44pp |
| 2021-12-31 | 13.83% | €499.65 Million ≈ $584.14 Million |
€3.61 Billion ≈ $4.22 Billion |
+12.26pp |
| 2020-12-31 | 1.58% | €20.00 Million ≈ $23.38 Million |
€1.27 Billion ≈ $1.48 Billion |
-- |
About Brii Biosciences Limited
Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neut… Read more